Edgewise Therapeutics Inc. Common Stock (EWTX)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Edgewise Therapeutics as a Graham-style bargain hunter, and I see a speculative clinical-stage biotech, not a proven business. At the 2026-10-13 close of $36.28, the market values it at $3.9B, yet it has no revenue in the filed statements. Losses are widening: in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$57.3M, or -$0.53 diluted EPS; in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$49.0M, or -$0.46. For FY2025 ended 2025-12-31, net income was -$167.8M and diluted EPS -$1.63, worse than FY2024's -$133.8M and FY2023's -$100.2M. Free cash flow is negative $158.8M trailing, a -4.0% FCF yield by FairStock's calculation. The balance sheet has little debt, with D/E 0.01, but Piotroski is 0/9 and the FairStock Score is 23/100. P/B is 8.72 and P/E is -19.61, both FairStock calculations from the close; without earnings, these are not value anchors. The moat is unproven: sevasemten and EDG-7500 are still in clinical trials, so future cash flows depend on trial outcomes and regulatory approval. Beta is 0.33, but the volatility of science is high. At this price, I see no margin of safety in present numbers; any value rests on pipeline hope. I would monitor cash burn, trial data, and financing needs.

In plain English: Edgewise Therapeutics is a small biotech trying to develop medicines for muscle disorders such as Duchenne and Becker muscular dystrophy. It has no revenue yet, is losing money, and the losses have grown; its future depends on clinical trials and regulatory approval. At the close on 2026-10-13 at $36.28, the price looks expensive compared with its current financial numbers, so most of the value rests on whether its experimental drugs succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer